Jardiance (empagliflozin) agreement marks Highmark's second outcomes-based contract this year
Continuing its efforts to address high prescription drug costs, Highmark Inc. today announced its latest outcomes-based contract with Boehringer Ingelheim for Jardiance® (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. Jardiance is a product in the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio. ... |